<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431805</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2015/41</org_study_id>
    <nct_id>NCT03431805</nct_id>
  </id_info>
  <brief_title>TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery</brief_title>
  <acronym>TRAAP2</acronym>
  <official_title>TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery :a Multicenter Randomised, Double Blind Placebo Controlled Trial (TRAAP2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to assess the impact of tranexamic acid (TXA) for preventing postpartum hemorrhage
      (PPH) following a cesarean section (CS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regarding the prevention of PPH, recent randomized controlled trials (RCTs) of unclear
      quality have suggested that TXA may reduce blood loss and maternal morbidity, while a
      Cochrane Collaboration review has concluded, that &quot;TXA (in addition to uterotonic
      medications) decreases postpartum blood loss and prevents PPH and blood transfusions
      following vaginal birth and CS in women at low risk of PPH based on studies of mixed quality.
      Further investigations are needed on efficacy and safety of this regimen for preventing PPH.

      Treatment, that is a 10-mL blinded vial of the study drug (either 1g TXA or placebo according
      to the randomization sequence), will be administered intravenously to the participant women
      during the third stage of labor of cesarean delivery.

      The follow-up visit will take place in the postpartum ward of the maternity unit, on D2
      postpartum. This stage will include a venous blood sample to measure plasma concentrations of
      Hb and Ht, urea and creatinemia, prothrombin time (PT), active prothrombin time (aPTT),
      aspartate and alanine transaminase, total bilirubin and fibrinogen, and the completion of a
      self-questionnaire about satisfaction by the women, as well as the assessment of the adverse
      events.

      At 8 weeks postpartum, a self-questionnaire assessing psychological status and well-being
      will be sent to the women. At 12 weeks postpartum, all participants will be contacted by
      phone to assess the incidence of thrombotic and any other significant events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>postpartum hemorrhage</measure>
    <time_frame>day 2</time_frame>
    <description>Incidence of PPH defined by a calculated blood loss &gt; 1000mL [Calculated estimated blood loss = estimated blood volume × (preoperative Ht - postoperative Ht)/preoperative Ht (where estimated blood volume (mL) = weight (Kg) × 85)] or red blood cell transfusion before day 2 postpartum. Preoperative Ht will be the most recent Ht within one week before delivery. Postoperative Ht will be measured at D2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean calculated blood loss &gt; 500mL</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean calculated blood loss &gt; 1500mL</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total mean calculated blood loss</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean gravimetrically estimated blood loss</measure>
    <time_frame>6 hours</time_frame>
    <description>by measuring the suction volume and swab weight; proportion of women requiring supplementary uterotonic treatment including sulprostone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of postpartum transfusion</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean or median number of units of red blood cells transfused</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of arterial embolisation or emergency surgery for PPH</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean peripartum change in haemoglobin</measure>
    <time_frame>day 2</time_frame>
    <description>difference between the most recent Hb within one week before delivery and at day 2 postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean peripartum change in hematocrit</measure>
    <time_frame>day 2</time_frame>
    <description>difference between the most recent Ht within one week before delivery and at day 2 postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>15, 30, 45, 60 and 120 minutes after delivery</time_frame>
    <description>bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure</measure>
    <time_frame>15, 30, 45, 60 and 120 minutes after delivery</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic blood pressure</measure>
    <time_frame>15, 30, 45, 60 and 120 minutes after delivery</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with nausea reported by caregivers</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with vomiting reported by caregivers</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with phosphenes reported by caregivers</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with dizziness reported by caregivers</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinemia</measure>
    <time_frame>day 2</time_frame>
    <description>micromol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urea</measure>
    <time_frame>day 2</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prothrombin time (PT)</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aspartate transaminase</measure>
    <time_frame>day 2</time_frame>
    <description>IU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine transaminase</measure>
    <time_frame>day 2</time_frame>
    <description>IU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total bilirubin</measure>
    <time_frame>day 2</time_frame>
    <description>micromol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total fibrinogen</measure>
    <time_frame>day 2</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with deep venous thrombosis confirmed by paraclinical exams</measure>
    <time_frame>within twelve weeks after the delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with pulmonary embolism confirmed by paraclinical exams</measure>
    <time_frame>within twelve weeks after the delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with myocardial infarction confirmed by paraclinical exams</measure>
    <time_frame>within twelve weeks after the delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with any thrombotic event confirmed by paraclinical exams</measure>
    <time_frame>within twelve weeks after the delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>seizure</measure>
    <time_frame>within twelve weeks after the delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal failure</measure>
    <time_frame>within twelve weeks after the delivery</time_frame>
    <description>defined by the need for dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>women's satisfaction</measure>
    <time_frame>day 2 and weeks 8 postpartum</time_frame>
    <description>assessed by a self-administered questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provider-assessed clinically significant PPH</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb drop &gt; 2g/DL</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active prothrombin time (aPTT)</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aspartate transaminase &gt; 2N</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine transaminase &gt; 2N (day 2)</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gravimetrically estimated blood loss &gt; 500mL</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gravimetrically estimated blood loss &gt; 1000 mL</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shock</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfer to Intensive Care Unit</measure>
    <time_frame>twelve weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>42 days postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4524</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloride solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Injectable Solution</intervention_name>
    <description>After the routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the woman within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped.</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride 0.9%</intervention_name>
    <description>After a routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes afterbirth), slowly (over 30-60 seconds), once the cord has been clamped.</description>
    <arm_group_label>Chloride solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  : adult women admitted for a cesarean delivery before or during labor, at a term ≥ 34
             weeks,

          -  hemoglobin level at the last blood sample &gt;9g/dl,

          -  available blood test for Hb and Ht within one week before caesarean delivery,

          -  informed signed consent

        Exclusion Criteria:

          -  previous thrombotic event or preexisting pro-thrombotic disease,

          -  epileptic state or history of seizures,

          -  presence of any chronic or active cardiovascular disease outside hypertension,

          -  any chronic or active renal disease and chronic or active liver disease at risk
             thrombotic or hemorrhagic, autoimmune disease,

          -  sickle cell disease,

          -  placenta praevia,

          -  placenta accreta/increta/percreta,

          -  abruption placentae,

          -  eclampsia,

          -  HELLP syndrome,

          -  significant hemorrhage before cesarean section

          -  in utero fetal death,

          -  administration of low-molecular-weight heparin or antiplatelet agents during the week
             before delivery,

          -  planned general anesthesia,

          -  hypersensitivity to tranexamic acid or concentrated hydrochloric acid,

          -  instrumental extraction failure,

          -  multiple pregnancy with vaginal delivery of the first child,

          -  poor understanding of the French language.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Loïc Sentilhes, MD,PfD</last_name>
    <phone>+335 56 79 55 79</phone>
    <email>loic.sentilhes@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Deneux-Tharaux, MD</last_name>
    <phone>+ 331 42 34 55 79</phone>
    <email>catherine.deneux-tharaux@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume Legendre, MD</last_name>
      <email>guillaume.legendre@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier Riethmuller, MD,PhD</last_name>
      <email>didier.riethmuller@univ-fcomte.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loic Sentilhes, MD,PhD</last_name>
      <email>loic.sentilhes@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Olivier delorme</last_name>
      <email>olivier.delorme@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muriel Doret, MD,PhD</last_name>
      <email>muriel.doret-dion@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delphine Vardon, MD</last_name>
      <phone>+336 66 93 52 86</phone>
      <email>vardon-d@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Estain</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis Gallot, MD,PhD</last_name>
      <email>dgallot@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raoul Desbrières, MD</last_name>
      <email>raoul.desbriere@orange.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florence Bretelle, MD,PhD</last_name>
      <email>florence.bretelle@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florent Fuchs, MD</last_name>
      <email>f-fuchs@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Morel, MD,PhD</last_name>
      <email>olivier.morel@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norbert Winer, MD,PhD</last_name>
      <email>norbert.winer@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>André Bongain, MD,PhD</last_name>
      <email>bongain.a@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Letouzey, MD,PhD</last_name>
      <email>vincent.letouzey@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles Kayem, MD,PhD</last_name>
      <email>gkayem@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph Paris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elie Azria, MD</last_name>
      <email>eazria@hpsj.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maternité de Port-Royal Paris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Goffinet, MD,PhD</last_name>
      <email>francois.goffinet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital universitaire Necker-Enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Salomon, MD,PhD</last_name>
      <email>laurentsalomon@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital universitaire Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Schmitz, MD,PhD</last_name>
      <email>thomas.schmitz@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière Paris</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeremy Sroussi, MD</last_name>
      <email>jeremy.sroussi@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital universitaire Kremlin-Bicètre</name>
      <address>
        <city>Paris</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Victoire Senat, MD,PhD</last_name>
      <email>marie-victoire.senat@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Poissy-Saint Germain</name>
      <address>
        <city>Poissy</city>
        <zip>78303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Rozenberg, MD,PhD</last_name>
      <email>prozenberg@chi-poissy-st-germain.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hélène Isly, MD,PhD</last_name>
      <email>helene.isly@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Maela Le Lous, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Verspyck, MD,PhD</last_name>
      <email>Eric.Verspyck@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Céline Chauleur, MD,PhD</last_name>
      <email>celine.chauleur@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Langer, MD,PhD²</last_name>
      <email>Bruno.Langer@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Paule de Viguier CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Guerby, MD</last_name>
      <email>guerby.p@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck Perrotin, MD,PhD</last_name>
      <email>franck.perrotin@med.univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized</keyword>
  <keyword>double blind placebo controlled trial</keyword>
  <keyword>prevention</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>postpartum hemorrhage</keyword>
  <keyword>cesarean</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

